Table 1.
Age-adjusted incidence rates and incidence rate ratios of small cell lung carcinoma and extrapulmonary small cell carcinoma according to primary site and gender, SEER-13, 1992-2010*
| ICD-O-3 | Males | Females | Male-to-female | ||||
|---|---|---|---|---|---|---|---|
| Site | topography codes | No. | IR | No. | IR | IRR | (95 % CI) |
| Total§ | 00.0-80.9 | 28,820 | 96.20 | 26,902 | 71.44 | 1.35 | (1.32, 1.37)† |
| SCLC | 34.0-34.9 | 26,798 | 89.19 | 25,161 | 66.88 | 1.33 | (1.31, 1.36)† |
| EPSCC | 00.0-33.9, 35.0-75.9, 77.0-77.9 | 1,272 | 4.41 | 1,166 | 3.06 | 1.44 | (1.33, 1.56)† |
| Salivary glands | 07.9-08.9 | 44 | 0.16 | <16 | ~ | ~ | |
| Esophagus | 15.0-15.9 | 106 | 0.36 | 81 | 0.21 | 1.72 | (1.27, 2.33)† |
| Stomach | 16.0-16.9 | 64 | 0.21 | 24 | 0.06 | 3.46 | (2.12, 5.80)† |
| Colon/rectum | 18.0-20.9 | 125 | 0.42 | 113 | 0.30 | 1.41 | (1.08,1.84)† |
| Anus | 21.0-21.8 | 16 | 0.05 | 21 | 0.06 | 0.95 | (0.46, 1.91) |
| Liver/intrahepatic bile ducts | 22.0-22.1 | 18 | 0.06 | <16 | ~ | ~ | |
| Gallbladder | 23.9 | <16 | ~ | 30 | 0.08 | ~ | |
| Pancreas | 25.0-25.9 | 89 | 0.30 | 84 | 0.22 | 1.38 | (1.01, 1.88)† |
| Nose, nasal cavity, middle ear | 30.0-30.1, 31.0-31.9 | 21 | 0.07 | 16 | 0.04 | 1.56 | (0.77, 3.21) |
| Larynx | 32.0-32.9 | 37 | 0.11 | 27 | 0.07 | 1.57 | (0.93, 2.68) |
| Breast | 50.0-50.9 | <16 | ~ | 68 | 0.18 | ~ | |
| Vagina | 52.9 | NA | NA | 37 | 0.10 | ~ | |
| Cervix | 53.0-53.9 | NA | NA | 260 | 0.69 | ~ | |
| Uterus | 54.0-55.9 | NA | NA | 56 | 0.15 | ~ | |
| Ovary | 56.9 | NA | NA | 111 | 0.29 | ~ | |
| Prostate | 61.9 | 206 | 0.73 | NA | NA | ~ | |
| Kidney and renal pelvis | 64.9, 65.9 | 22 | 0.07 | <16 | ~ | ~ | |
| Urinary bladder | 67.0-67.9 | 411 | 1.48 | 118 | 0.30 | 4.91 | (3.99, 6.09)† |
| Unknown primary | 76.0-76.8, 80.9 | 750 | 2.61 | 575 | 1.50 | 1.73 | (1.55, 1.94)† |
Abbreviations: CI confidence interval, EPSCC extrapulmonary small cell carcinoma, ICD-O-3 third edition of the International Classification of Diseases for Oncology, NA not applicable, No. number of cases, SCLC small cell lung carcinoma, SEER-13 13 cancer registry areas of the Surveillance, Epidemiology and End Results Program, ~ IRs and IRRs are not calculated for <16 cases.
*Incidence rates are age-adjusted to the 2000 U.S. standard population and expressed per 1,000,000 person-years. IRRs are based on unrounded rates.
†95 % CI excludes 1.00 (based on unrounded upper and lower CI), and IRR is significant (P < 0.05).
§Specified sites with 1–15 total cases not shown in the table (ICD-O-3 code): tongue (01.1-0.29), gum and other mouth (03.0-03.9, 05.0-05.9, 06.0-06.9), tonsil (09.0-09.9), oropharynx (10.0-10.9), hypopharynx (12.9, 13.0-13.9), other oral cavity and pharynx (14.0-14.8), small intestine (17.0-17.9), intestinal tract, unspecified (26.0-26.9), soft tissues, including heart (38.0, 47.0-47.9 49.0-49.9), retroperitoneum/peritoneum (48.0-48.8), vulva (51.0-51.9), other female genital (57.0-58.9), testis (62.0-62.9), other male genital (63.0-63.9), ureter (66.9), eye and orbit (69.0-69.9), thyroid (73.9), other endocrine (37.9, 74.0-74.9, 75.0-75.9), and lymph nodes (77.0-77.9). Sites with >15 cases, but with fewer than 16 among both, males and females, not specified in the table (No., IR, ICD-O-3 code): nasopharynx (No. = 23; IR = 0.03; 11.0-11.9), other biliary (No. = 19; IR = 0.03; 24.0-24.9), and trachea/mediastinum/other respiratory (No. = 25; IR = 0.04; 33.9, 38.1-39.9).